Going beyond the obvious in RAS driven cancers
With all the attention on drugging BRAF and KRAS over the last decade, we have seen a gradual move from pan to selective inhibitors against V600E and G12C/G12D, respectively, as well as novel approaches against multiple KRAS mutations through SOS1 emerging.
Beyond these approaches, what does the future potentially hold?
To be clear, I’m not talking about overcoming resistance such as SHP2, but rather a different kettle of fish altogether.
New companies and RAS/RAF agents on the horizon
It turns out there are quite a few biotechs (public and private) who are doing some creative work behind the scenes – think discovery and preclinical developments you may not have heard much about.
It’s time to turn our attention to new therapeutics on the horizon.
We have posted interviews involving three of these biotechs in the past, but the majority of the dozen selections we have chosen for this latest review are very much newcomers on BSB…
What’s not to like?
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
